Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (6): 107-113.doi: 10.6040/j.issn.1671-7554.0.2021.1237

Previous Articles    

Long-acting injectable application in patients with schizophrenia in communities of three provinces: current status and problems

LI Jiabo1,2, OUYANG Jiangfeng3, YANG Ding1,2, GAO Jing1,2, SUN Qiang1,2   

  1. 1. Center for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. NHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan 250012, Shandong, China;
    3. Zhucheng Center for Disease Control and Prevention, Zhucheng 262200, Shandong, China
  • Published:2022-06-17

PDF (PC)

570

Abstract: Objective To analyze the current status and problems of long-acting injectable(LAI)application in patients with schizophrenia in communities of three provinces, so as to provide reference for promoting its application and promotion. Methods Purpose sampling was used to select Yunfu, Chengdu and Linyi according to the principle of maximum differentiation. Data were obtained through interviews with various stakeholders.Thematic framework approach was adopted for analysis, and nonparametric test was used to compare the frequency differences of common concerns among the three sample areas. Results The three sample areas were comparable in the acceptance degree, injection qualification and support policies of LAI, but there were differences in the application scope, inclusion criteria, injection location, capital guarantee and participating departments.There were also problems in the application of LAI in patients with schizophrenia in communities, such as limitations in cognitive and treatment concept, insufficient access to treatment, insufficient funding sustainability, inadequate involvement and collaboration of departments, and so on. Conclusion The sample areas have both similarities and differences in the current status of LAI application in patients with schizophrenia in communities. For the existing problems, the following measures are necessary: strengthen publicity and communication; provide LAI for patients as soon as possible; implement a more reasonable injection scheme according to local conditions; reduce injection prices; formulate and implement reasonable medical insurance policies; give full play to the organization and coordination role of relevant government departments.

Key words: Long-acting injectable, Communities, Schizophrenia, Comparative study

CLC Number: 

  • R749.3
[1] 中华医学会精神医学分会精神分裂症协作组. 抗精神病药长效针剂治疗精神分裂症的专家共识[J]. 中华精神科杂志, 2020(2): 99-100. Chinese Schizophrenia Coordination Group. Expert consensus on long-acting injectable in the treatment of schizophrenia[J]. Chinese Journal of Psychiatry, 2020(2): 99-100.
[2] 李喆, 杨亚黎, 吴胜利, 等. 严重精神障碍患者社区规范管理模式及实施效果研究[J]. 中国全科医学, 2018, 21(35): 4322-4327. LI Zhe, YANG Yali, WU Shengli, et al. Effect of community-based standardized mental disorders management onpatients with severe mental disorders[J]. Chinese General Practice, 2018, 21(35): 4322-4327.
[3] 赵靖平. 中国精神分裂症防治指南[M]. 2版. 北京:中华医学电子音像出版社, 2015:1-2.
[4] 中华医学会精神医学分会精神分裂症协作组. 抗精神病药长效针剂在精神分裂症治疗中的作用[J]. 中华精神科杂志, 2020(3):163-170. Chinese Schizophrenia Coordination Group. Long-acting injectable in the treatment of schizophrenia[J]. Chinese Journal of Psychiatry, 2020(3):163-170.
[5] 舒良, 王刚. 棕榈酸帕利哌酮注射液个案报告概述[J]. 中国心理卫生杂志, 2012, 26(B06): 42. SHU Liang, WANG Gang. Summary of case report of paliperidone palmitate injection[J]. Chinese Mental Health Journal, 2012, 26(B06): 42.
[6] Jari T, Ellenor MR, Maila M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia [J]. JAMA Psychiatry, 2017, 74(7): 686-693.
[7] 人力资源社会保障部. 关于印发国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)的通知(人社部发〔2017〕15号)[EB/OL].(2017-02-21)[2021-07-09]. http://www.mohrss.gov.cn/wap/zc/zcwj/201702/t20170223_266775.html.
[8] 中华人民共和国国家卫生健康委员会. 严重精神障碍管理治疗工作规范(2018年版)[J]. 中国实用乡村医生杂志, 2018, 25(7): 11-22. National Health Commission of the peoples Republic of China. Norms for the management and treatment of severe mental disorders(2018 Edition)[J]. Chinese Practical Journal of Rural Doctor, 2018, 25(7): 11-22.
[9] 唐伟, 杨馥银, 温娜, 等. 棕榈酸帕利哌酮长效针剂与利培酮治疗首次发病精神分裂症患者的随机对照研究[J]. 中华精神科杂志, 2016, 49(2): 76-80. TANG Wei, YANG Fuyin, WEN Na, et al. A comparative study of paliperidone palmitate injections and risperidone on long-term effects and prognosis for the first-episode schizophrenic patients[J]. Chinese Journal of Psychiatry, 2016, 49(2): 76-80.
[10] 陈礼贤, 翁小娟, 徐丹红, 等. 长效针剂对轻中度精神分裂症患者的临床治疗效果[J]. 中国医师杂志, 2020, 22(4): 592-595. CHEN Lixian, WENG Xiaojuan, XU Danhong, et al. Clinical therapeutic effect of long-acting injection on patients with mild to moderate schizophrenia[J]. Journal of Chinese Physician, 2020, 22(4): 592-595.
[11] 胡晓松, 赵燕, 吴尊友. 云南省文山州HIV感染者抗病毒治疗脱失影响因素的定性研究[J]. 中华疾病控制杂志, 2018, 22(8): 822-825. HU Xiaosong, ZHAO Yan, WU Zunyou. Qualitative study of factors associated with antiretroviral therapy drop-out among HIV-infected patients in Wenshan prefecture, Yunnan Province[J]. Chinese Journal of Disease Control & Prevention, 2018, 22(8): 822-825.
[12] 汪涛, 陈静, 胡代玉, 等. 运用主题框架法进行定性资料分析[J]. 中国卫生资源, 2006,9(2): 86-88. WANG Tao, CHEN Jing, HU Daiyu, et al. Thematic framework method was used for qualitative data analysis[J]. Chinese Health Resources, 2006, 9(2): 86-88.
[13] 新华社. 国家卫生计生委等部门发布合理用药十大核心信息[EB/OL].(2013-12-10)[2021-10-04]. http://www.gov.cn/jrzg/2013-12/10/content_2545748.htm.
[14] 宓为峰, 马文斌, 熊健, 等. 精神分裂症患者用药依从性及复发情况的调查[J]. 中华精神科杂志, 2012, 45(1): 25-28. MI Weifeng, MA Wenbin, XIONG Jian, et al. Compliance with antipsychotic treatment and relapse in schizophrenia[J]. Chinese Journal of Psychiatry, 2012, 45(1): 25-28.
[15] 黄悦勤. 中国精神卫生调查概况[J]. 心理与健康, 2018(10): 14-16. HUANG Yueqin. Survey of mental health in China[J]. Psychology & Health, 2018(10): 14-16.
[16] Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies[J]. World Psychiatry, 2013, 12(3): 216-226.
[17] Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition [J]. Am J Psychiatry, 2004, 161(2 Suppl): 1-56.
[18] Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects [J]. World J Biol Psychiatry, 2013, 14(1): 2-44.
[19] Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology [J]. J Psychopharmacol, 2011, 25(5): 567-620.
[20] Remington G, Addington D, Honer W, et al. Guidelines for the Pharmacotherapy of Schizophrenia in Adults [J]. Can J Psychiatry, 2017, 62(9): 604-616.
[21] Weiden PJ, Kim E, Bermak J, et al. Does Half-life matter after antipsychotic discontinuation? a relapse comparison in schizophrenia with 3 different formulations of paliperidone [J]. J Clin Psychiatry, 2017, 78(7): e813-e820.
[22] Magnusson MO, Samtani MN, Plan EL, et al. Dosing and switching strategies for paliperidone palmitate 3-month formulation in patients with schizophrenia based on population pharmacokinetic modeling andsimulation, and clinical trial data [J]. CNS Drugs, 2017, 31(4): 273-288.
[23] Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia [J]. Schizophr Res, 2015, 169(1-3): 393-399.
[24] Munday J, Greene M, Chang E, et al. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data [J]. Curr Med Res Opin, 2019, 35(7): 1231-1239.
[25] Kane JM, Schooler NR, Marcy P, et al. Patients with early-phase schizophrenia will accept treatment with sustained-release medication(long-acting injectable antipsychotics): results from therecruitment phase of the PRELAPSE trial [J]. J Clin Psychiatry, 2019, 80(3): 18m12546. doi: 10.4088/JCP.18m12546.
[26] Chiou CF, Wang BC, Caldwell R, et al. The cost reduction in hospitalization associated with paliperidone palmitate in the Peoples Republic of China, Korea, and Malaysia [J]. Neuropsychiatr Dis Treat, 2015, 11(6): 1989-1994.
[27] Baser O, Xie L, Pesa J, et al. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics [J]. J Med Econ, 2015, 18(5): 357-365.
[28] Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in france [J]. Pharmacoeconomics, 2016, 34(4): 363-391.
[29] Lefebvre P, Muser E, Joshi K, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia and comorbid substance abuse [J]. Clin Ther, 2017, 39(7): 1380-1395.
[30] 周宇, 傅启伟, 黄牡婵. 棕榈酸帕利哌酮长效针剂治疗精神疾病双相障碍近远期效果分析[J]. 中国药事, 2018, 32(6): 799-803. ZHOU Yu, FU Qiwei, HUANG Muchan. Short-term and long-termeffects of paliperidonepalmitatelong-actinginjection in treating mental illness in bipolar disorder[J]. Chinese Pharmaceutical Affairs, 2018, 32(6): 799-803.
[1] LIU Yingjun, ZHANG Tao, WANG Lu, LIU Jia, CHANG Xuerun, ZHANG Jingxuan, XUE Fuzhong. Serum metabolic profiling of schizophrenia based on random forest [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 92-96.
[2] GONG qing, ZHANG Hao, QIAO Ying. Investigation on quality of life in family members of the schizophreniac [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(Z2): 177-178.
[3] ZHAO Yan1, WANG Gang1, CHEN Dafang2, CHENG Yuhang1, CHEN Xueyan1. Plasma levels of IL-6, IL-10 and IL-12 and influencing factors in first-episode and neuroleptic-free schizophrenia patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 70-73.
[4] LI Yang, CAO Fenglin, ZHONG Gengkun, LIN Pingzhen, LIANG Xinhao. Ecological executive function in adolescent relatives of schizophrenia patients and its relationship with victimization [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 86-91.
[5] YANG Li-min1,2, WANG Yan1, SUN Meng-meng2, CUI Kai-yan2, WANG Li-na2, LIU Lan-fen1,2. Information processing speed and related factors in first-episode schizophrenia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(9): 100-104.
[6] WANG Yan1, YANG Li-min1,2, SUN Meng-meng2, CUI Kai-yan2, YANG Xiao-dong2, QIAO Dong-dong1,2, WANG Ru-zhan2, ZHANG Jing-xuan2, LIU Lan-fen1,. Relationship between personality traits and childhood trauma in patients with schizophrenia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(8): 103-106.
[7] XU Yun-lu1, XU Cheng-min2. Relativities of stigma in schizophrenia with social support and consciousness of social face [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(11): 90-92.
[8] LIU Zhenhua1, ZHENG Yunshao2, ZHANG Tianliang2, AN Luxuan1. Efficacy of paliperidone extended-release tablets on improving  social function in acute patients with schizophrenia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(8): 100-103.
[9] PAN Hong,WANG Li-hua,MA Lu-xin. Pentacam and IOLMaster in keratometry and anterior chamber depth measurements: a contrast study [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(6): 624-627.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd